The results indicated that HER2-RQDs nanoprobes preferentially targeted and killed gastric cancer MGC803 cells, enabling imaging of subcutaneous tumors within 3 h post-injection and in-situ gastric tumors by 6 h post-injection. This evidence concerns the gene ERBB2 and gastric cancer.